Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc is poised for substantial growth as its Alzheimer's candidate, PMN310, shows a promising safety profile, lacking the amyloid-related imaging abnormalities (ARIA) that have impacted other therapies, which may enhance its market potential. The ongoing Phase Ib PRECISE-AD study is progressing rapidly, with more than 85% enrollment completed, positioning the company to release substantial data by mid-2026, further validating its therapeutic approach. With a massive and growing commercial opportunity in the Alzheimer's market, the continued positive developments in PMN310 reinforce a favorable outlook for the company's stock.

Bears say

ProMIS Neurosciences Inc reported a significant net loss of $11.6 million in 3Q25, equating to a loss of $0.24 per share, which underscores ongoing financial challenges. The company faces multiple risks that threaten its future, including the potential failure of PMN310 to demonstrate safety and efficacy in clinical trials, as well as the risk of needing to raise additional funds before achieving cash flow positivity. Additionally, competition in the market is intensifying, which may hinder market uptake of its therapies and could lead to future partnership uncertainties.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.